Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27791475 | 0.82 | S1PR1 (0.32) | HTR2AHTR2CKCNH2 | |
| SCHEMBL803799 | 0.80 | HIF1A (0.32) | — | |
| SCHEMBL27770205 | 0.80 | HTR2A (0.32) | HTR2AHTR2CKCNH2KDM4EALDH1A1 | |
| SCHEMBL13285903 | 0.79 | ESR1 (0.33) | HTR2AHTR2CKCNH2KDM4EALDH1A1 | |
| SCHEMBL13285988 | 0.79 | TLR9 (0.37) | MAOADYRK1AHTR2AHTR2CKCNH2 | |
| SCHEMBL803802 | 0.78 | BCHE (0.36) | HTR2AHTR2CKCNH2ALDH1A1 | |
| SCHEMBL804035 | 0.78 | HTR2A (0.34) | HTR2AHTR2CKCNH2 | |
| SCHEMBL10283243 | 0.78 | HTR2A (0.39) | HTR2AHTR2CKCNH2 | |
| SCHEMBL10283239 | 0.77 | HTR2A (0.32) | HTR2AHTR2CKCNH2 | |
| SCHEMBL27711877 | 0.77 | KDM4E (0.44) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-10 | — | — | US | disclosed |
| US-8143244-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-8129367-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-8124601-B2 | Compounds for the treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-28 | — | — | US | disclosed |
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20100216774-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-06-25 | — | — | US | disclosed |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008112851-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-09-18 | — | — | US | disclosed |
| WO-2008111978-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| US-20080188458-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-08-07 | — | — | US | disclosed |
| US-20080171015-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-17 | — | — | US | disclosed |
| US-7399758-B2 | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-07-15 | — | — | US | disclosed |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | BRISTOL-MYERS SQUIBB COMPANY | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311480-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | MAOA 1685/4885DYRK1A 4724/4885HTR2A 1907/4885 |
| US-20080188458-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MAOA 1590/4885DYRK1A 4880/4885HTR2A 4583/4885 |
| US-20080226590-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MAOA 1590/4885DYRK1A 4880/4885HTR2A 4583/4885 |
| US-20120115847-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MAOA 1590/4885DYRK1A 4880/4885HTR2A 4583/4885 |
| US-20080226592-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, OAT | MAOA 1868/4885DYRK1A 4848/4885HTR2A 4584/4885 |
| US-20080227769-A1 | Compounds for the Treatment of Hepatitis C | SLC10A1, HAVCR2, NR1H4 | MAOA 1799/4885DYRK1A 4850/4885HTR2A 4629/4885 |
| US-20080146537-A1 | 3,8-Diazabicyclo[3.2.1]octane-3-carboxylic acid, 8-[[8-cyclohexyl-5-[[[(dimethylamino)sulfonyl]amino]carbonyl]-1,12b-dihydro-11-methoxycycloprop[d]indolo[2,1-a][2]benzazepin-1a(2H)-yl]carbonyl]-, phenylmethyl ester; RNA polymerase inhibitor; liver disease, including cirrhosis and hepatocellular carcinoma | ZC3HAV1, ODC1, MED1 | MAOA 1441/4885DYRK1A 4853/4885HTR2A 3530/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | MAOA 2994/4885DYRK1A 4620/4885HTR2A 4863/4885 |
| US-20100216774-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, EIF2AK2, HCCS | MAOA 2669/4885DYRK1A 4645/4885HTR2A 2163/4885 |
| US-20090162318-A1 | Cyclopropyl Fused Indolobenzazepine HCV NS5B Inhibitors | HAVCR2, ZC3HAV1, HCCS | MAOA 1685/4885DYRK1A 4724/4885HTR2A 1907/4885 |
| US-20080171015-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MAOA 1590/4885DYRK1A 4880/4885HTR2A 4583/4885 |
| US-20080226591-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, HCCS, SLC10A1 | MAOA 1590/4885DYRK1A 4880/4885HTR2A 4583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.